Contract research, development and manufacturing organisation (CRDMO) BioDuro has opened a novel high potency compound synthesis laboratory in Shanghai, China.
The laboratory, located in the city's Waigaoqiao district, will produce highly potent active pharmaceutical ingredients (HPAPIs) at the hundred gram scale.
This will facilitate the company's ability to expedite its clients' discovery and early development programmes — covering therapeutic areas such as drug conjugates, antibody-drug conjugates (ADCs) peptide-drug conjugates (PDCs) and radionuclide-drug conjugates (RDCs).
Operating within occupational exposure band 5 (OEB-5), the facility is equipped to guarantee the safe and timely production of highly potent compounds.
The laboratory houses isolators, closed system reactors and a dedicated HEPA-filered HVAC system — all operated by trained technicians.
“The addition of this OEB-5 lab strengthens BioDuro’s capabilities in the development of highly potent drugs,” said CEO of BioDuro, Dr Armin Spura.
“As demand continues to grow for complex conjugated therapeutics, we remain committed to enhancing our capabilities and capacities, providing integrated solutions across chemistry, biology, and DMPK to accelerate the delivery of innovative treatments for global patients.”